公开(公告)号：US20240252441A1

公开(公告)日：2024-08-01

申请号：US18425556

申请日：2024-01-29

Applicant: CRITITECH, INC.

Inventor： Gere S. DIZEREGA ,  Michael BALTEZOR ,  Sam CAMPBELL ,  Charles J. DECEDUE ,  Matthew MCCLOREY ,  Holly MAULHARDT

IPC: A61K9/16 ,  A61K9/00 ,  A61K31/337 ,  A61K39/00 ,  C07K16/28

CPC classification number: A61K9/1652 ,  A61K31/337 ,  C07K16/2818 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053 ,  A61K2039/54

Abstract: Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.

公开(公告)号：US20230364021A1

公开(公告)日：2023-11-16

申请号：US18354293

申请日：2023-07-18

Applicant: CRITITECH, INC.

Inventor： Jacob SITTENAUER ,  Joseph FARTHING ,  Mark WILLIAMS ,  Michael BALTEZOR ,  Gere DIZEREGA ,  Aranza Barreda ABARCA ,  Shelby CLARK

IPC: A61K9/16 ,  A61K31/44 ,  A61K9/10 ,  A61K47/26 ,  A61K47/38 ,  A61K47/32

CPC classification number: A61K9/1688 ,  A61K31/44 ,  A61K9/10 ,  A61K47/26 ,  A61K47/38 ,  A61K47/32

Abstract: Particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof are provided, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm, as are methods for their use, and methods for making such particles.

公开(公告)号：US20220241257A1

公开(公告)日：2022-08-04

申请号：US17381705

申请日：2021-07-21

Applicant: CRITITECH, INC.

Inventor： Jacob SITTENAUER ,  Joseph FARTHING ,  Mark WILLIAMS ,  Michael BALTEZOR ,  Gere DIZEREGA ,  Aranza Barreda ABARCA ,  Shelby CLARK

IPC: A61K31/44 ,  A61K9/16

Abstract: The disclosure provides particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 μm and about 8 μm, methods for their use, and methods for making such particles.

公开(公告)号：US20210387961A1

公开(公告)日：2021-12-16

申请号：US17401654

申请日：2021-08-13

Applicant: CRITITECH, INC.

Inventor： Mark WILLIAMS ,  Jacob SITTENAUER ,  Shelby CLARK ,  Joseph FARTHING ,  Michael BALTEZOR ,  Matthew MCCLOREY

IPC: C07D401/10 ,  A61P31/04 ,  A61K9/14 ,  A61K9/00

Abstract: The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

公开(公告)号：US20200163928A1

公开(公告)日：2020-05-28

申请号：US16776919

申请日：2020-01-30

Applicant: CRITITECH, INC.

Inventor： Michael BALTEZOR ,  Joseph FARTHING ,  Jake SITTENAUER ,  Jahna ESPINOSA ,  Samuel CAMPBELL ,  Matthew MCCLOREY ,  Julia K. FISCHER ,  Mark D. WILLIAMS ,  Gary E. CLAPP

IPC: A61K31/337 ,  A61K9/51 ,  A61K9/16 ,  B05B13/02 ,  A61K9/10 ,  A61K9/00 ,  A61J3/02 ,  B01J3/00 ,  B05B1/34 ,  B01D46/24 ,  B01J4/00 ,  B01J19/10 ,  B01J2/04 ,  A61K9/14 ,  B01J19/26 ,  B01J3/02

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

公开(公告)号：US20170224650A1

公开(公告)日：2017-08-10

申请号：US15499397

申请日：2017-04-27

Applicant: CRITITECH, INC.

Inventor： Michael BALTEZOR ,  Joseph FARTHING ,  Jake SITTENAUER ,  Jahna ESPINOSA ,  Samuel CAMPBELL ,  Matthew MCCLOREY ,  Julia K. FISCHER ,  Mark D. WILLIAMS

IPC: A61K31/337 ,  B01J3/00 ,  B01J3/02 ,  A61K9/16

CPC classification number: A61K31/337 ,  A61J3/02 ,  A61K9/0019 ,  A61K9/10 ,  A61K9/14 ,  A61K9/1605 ,  A61K9/1682 ,  A61K9/1688 ,  A61K9/5192 ,  B01D46/24 ,  B01D2271/02 ,  B01J2/04 ,  B01J3/008 ,  B01J3/02 ,  B01J4/002 ,  B01J19/10 ,  B01J19/26 ,  B05B1/3489 ,  B05B13/0278 ,  B05D2401/90

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

公开(公告)号：US20230142186A1

公开(公告)日：2023-05-11

申请号：US18053557

申请日：2022-11-08

Applicant: CRITITECH, INC.

Inventor： Jacob SITTENAUER ,  Aranza Barreda ABARCA ,  Shelby CLARK ,  Joseph FARTHING ,  Mark WILLIAMS ,  Gere DIZEREGA ,  Michael BALTEZOR

IPC: A61K31/55 ,  A61K9/16

CPC classification number: A61K31/55 ,  A61K9/1688 ,  A61K9/16

Abstract: Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m2/g, methods for their use, and methods for their production are provided.

公开(公告)号：US20200247780A1

公开(公告)日：2020-08-06

申请号：US16650670

申请日：2018-09-28

Applicant: CRITITECH, INC.

Inventor： Mark WILLIAMS ,  Jacob SITTENAUER ,  Shelby CLARK ,  Joseph FARTHING ,  Michael BALTEZOR ,  Matthew MCCLOREY

IPC: C07D401/10 ,  A61K9/14 ,  A61K9/00 ,  A61P31/04

Abstract: The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

公开(公告)号：US20200246355A1

公开(公告)日：2020-08-06

申请号：US16650961

申请日：2018-09-28

Applicant: CRITITECH, INC.

Inventor： Michael BALTEZOR ,  Matthew MCCLOREY ,  Joseph S. FARTHING ,  Mark WILLIAMS ,  Jacob SITTENAUER

IPC: A61K31/569 ,  A61K9/00 ,  A61K9/16 ,  A61K31/496 ,  A61P9/00

Abstract: Disclosed herein are particles of at least 95% by weight of a glucocorticoid that have a specific surface area of at least 10 m2/g, methods for making, such particles, and methods for their use as therapeutics. Also disclosed herein are particles of at least 95% by weight of an indolinone that have a specific surface area of at least 10 m2/g, methods for making such particles, and methods for-their use as therapeutics.

公开(公告)号：US20190209514A1

公开(公告)日：2019-07-11

申请号：US16239527

申请日：2019-01-04

Applicant: CRITITECH, INC.

Inventor： Gere S. DIZEREGA ,  Michael BALTEZOR ,  Charles J. DECEDUE ,  Sam CAMPBELL ,  Matthew MCCLOREY

IPC: A61K31/337 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K9/14 ,  A61P35/00

CPC classification number: A61K31/337 ,  A61K9/0019 ,  A61K9/0034 ,  A61K9/08 ,  A61K9/10 ,  A61K9/14 ,  A61K9/16 ,  A61K47/26 ,  A61P35/00

Abstract: Disclosed herein are methods for treating and inhibiting the recurrence of bladder cancer by local administration of compositions comprising taxane particles such as docetaxel particles. Administration methods include intratumoral injection, direct injection into surgical tumor resection sites, and intravesical instillation.